Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The generic pharmaceutical market is on the rise as product innovation declines and patented drugs lose their exclusive rights. It is expected that generic drugs will become widespread in almost all major pharmaceutical markets by 2020, with a particular focus on this trend in India and China. This shift has created a competitive landscape where manufacturers of patented therapies must now contend with generic drug manufacturers.
As the generic pharmaceutical market gains prominence, manufacturers are increasingly prioritizing cost reduction to stay competitive. This heightened competition has prompted pharmaceutical innovators to explore more efficient manufacturing processes to maintain their market share. Traditionally, cost-cutting measures were implemented in the later stages of clinical development, but the growing pressure to save money has led innovators to empower their employees to develop the necessary skills for cost-effective production.
One strategy employed by pharmaceutical innovators is the investment in new technologies to enhance the productivity and efficiency of manufacturing intermediates for drugs like duloxetine. Duloxetine is a medication used to treat major depressive disorder and chronic musculoskeletal pain. The main brand of duloxetine, Cymbalta, lost its patent protection in December 2015, opening up opportunities for cost reduction in its production.
One key area of innovation in cost reduction is the use of biocatalysts in the manufacturing process. Biocatalysts are substances that accelerate chemical reactions, and in the pharmaceutical industry, they play a crucial role in reducing costs while maintaining a sustainable and environmentally friendly manufacturing process. Incorporating biocatalysts in the production of duloxetine can lead to significant cost savings without compromising the quality of the active pharmaceutical ingredient (API).
By adopting more effective manufacturing processes and embracing new technologies, pharmaceutical innovators aim to not only cut costs but also to maintain the quality and efficacy of their products. This strategic approach is essential in the face of increasing competition from generic drug manufacturers who benefit from lower production costs due to the absence of research and development expenses.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|
Duloxetine Atorvastatin Intermediates Market Highlights:
Duloxetine Intermediate and Atorvastatin Intermediates Market Overview
The duloxetine intermediate and atorvastatin intermediates market is expected to reach USD 68.12 Million by 2030 at 3.90% CAGR during the forecast period 2022-2030. Duloxetine intermediate is a serotonin-norepinephrine reuptake inhibitor (SNRI) which is widely approved for the treatment of stress urinary incontinence in women, major depressive disorder (MDD), and other chronic diseases. The atorvastatin intermediate is commonly used in lowering the cholesterol level and helps prevent cardiovascular diseases.
Rising prevalence of major depressive disorder (MOD), the growing importance of generics, increasing demand for atorvastatin intermediate, rising incidence of chronic diseases are expected to enhance the duloxetine intermediate and atorvastatin intermediates market growth. However, factors such as increasing healthcare cost and unfavorable drug price control policies across various countries may restrain the duloxetine intermediate and atorvastatin intermediates market growth during the forecast period.
Market Dynamics
The duloxetine intermediate and atorvastatin intermediates market has been primarily driven by the rising prevalence of major depressive disorder (MOD), the growing importance of generics, increasing demand for atorvastatin intermediate, and growing incidence of chronic diseases. For instance, as per the survey carried out by the American Heart Association and the American College of Cardiology in 2016, around 37.5% (43.2 million) to 48.6% (56 million) of the US adults were on treatment by atorvastatin intermediate. Factors such as rising healthcare cost, unfavorable drug price control policies across various countries may restrain the duloxetine intermediate and atorvastatin intermediates market growth during the forecast period.
Global Duloxetine Intermediate and Atorvastatin Intermediates Market Revenue, by Intermediate, 2017 & 2023 (USD Million) Â 
Sources: MRFR Analysis
Segmentation
The duloxetine intermediate and atorvastatin intermediates market is segmented into an intermediate type. Based on intermediate, the market is bifurcated into duloxetine intermediates and atorvastatin intermediates. Duloxetine Intermediate segment held a duloxetine intermediate and atorvastatin intermediates market share of 32393.03 USD Million in 2017.
Key Players
The prominent players in the Duloxetine Intermediate and Atorvastatin Intermediates market are Jiangxi Aifeimu Technology Co., Ltd, Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Jigs Chemicals, Manus Aktteva, Arch Pharmalabs, Afine Chemicals Ltd, Shodhana Laboratories, Fluorochem Ltd, Chiral Bio Sciences Ltd, Tokyo Chemical Industry Co., Ltd.
Asia-Pacific Duloxetine Intermediate and Atorvastatin Intermediates Market Share, 2017 (%) Â 
  Â
Sources: MRFR Analysis
Regional Analysis
The duloxetine intermediate and atorvastatin intermediates market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas accounts the largest market share, wherein North America is expected to dominate the market mainly due to the increasing geriatric population and the availability of advanced healthcare facilities in this region.
Europe is anticipated to account for the second-largest market share during the forecast period. The factors responsible for market growth in this region are well-established healthcare infrastructure and the increase in adoption of duloxetine intermediate and atorvastatin intermediates for the treatment of various chronic disease and major mental disorders.
Asia-Pacific is estimated to be the fastest-growing region in the duloxetine intermediate and atorvastatin intermediates market. This can be attributed to developing economies such as China, India, and South Korea emerging as major destinations for the outsourcing of clinical trials, drug manufacturing, and pathology testing. Japan held a market share of 18.5% in 2017.
Also, the duloxetine intermediate and atorvastatin intermediates market in the Middle East and Africa region is projected to account for the least share during the review period. The Middle East is expected to influence the market owing to the increasing use of duloxetine intermediate and atorvastatin intermediates for the treatment of various chronic disorders in Saudi Arabia, Kuwait, and the UAE.
Market Segmentation
Duloxetine Intermediate and Atorvastatin Intermediates Market, by Intermediate Type
- Duloxetine Intermediates
- Atorvastatin Intermediates
Duloxetine Intermediate and Atorvastatin Intermediates Market, by Region
-
Americas- North America
- US
- Canada
- Latin America
- North America
-
Europe- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
-
Asia-Pacific- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
-
Middle East & Africa- Middle East
- Africa
Available Additional Customizations
Intended Audience
- Duloxetine intermediate & atorvastatin intermediates manufacturers
- Healthcare providers
- Research institutes and academic centers
- Government associations
- Market research and consulting
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
